These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11101192)

  • 21. Mibefradil, a T-type channel-selective calcium antagonist: clinical trials in chronic stable angina pectoris.
    Massie BM
    Am J Hypertens; 1998 Apr; 11(4 Pt 3):95S-102S. PubMed ID: 9607373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The T- and L-type calcium channel blocker (CCB) mibefradil attenuates leg edema induced by the L-type CCB nifedipine in the spontaneously hypertensive rat: a novel differentiating assay.
    Major TC; Dhamija S; Black N; Liachenko S; Morenko B; Sobocinski G; Okerberg C; Tinholt P; Madore S; Kowala MC
    J Pharmacol Exp Ther; 2008 Jun; 325(3):723-31. PubMed ID: 18326812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beneficial effects of the T- and L-type calcium channel antagonist, mibefradil, against exercise-induced myocardial stunning in dogs.
    Parent de Curzon O; Ghaleh B; Hittinger L; Giudicelli JF; Berdeaux A
    J Cardiovasc Pharmacol; 2000 Feb; 35(2):240-8. PubMed ID: 10672856
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of calcium channel blockers and beta-adrenoceptor blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. Netherlands Working Group on Cardiovascular Research (WCN).
    Van Der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
    Br J Clin Pharmacol; 1999 May; 47(5):493-8. PubMed ID: 10336572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. T-channel-selective calcium channel blockade: a promising therapeutic possibility, only preliminarily tested so far: a review of published data. T-Channel Calcium Channel Blocker Study Group.
    Van der Vring JA; Cleophas TJ; Van der Wall EE; Niemeyer MG
    Am J Ther; 1999 Jul; 6(4):229-33. PubMed ID: 11329102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. T- and L-type Ca2+-channel antagonists reduce contractility in guinea pig cardiac myocytes.
    Hoischen S; Brixius K; Schwinger RH
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):323-30. PubMed ID: 9700997
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different effects of calcium antagonist and beta-blocker therapy on left-ventricular diastolic function in ischemic heart disease. A direct comparison of the impact of mibefradil and atenolol.
    Hassager C; Thygesen K; Grande P; Fischer Hansen J; Mickley H; Gustafsson I; Skagen K; Steensgaard-Hansen F
    Cardiology; 2001; 96(2):65-71. PubMed ID: 11740134
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The angiographic and clinical benefits of mibefradil in the coronary slow flow phenomenon.
    Beltrame JF; Turner SP; Leslie SL; Solomon P; Freedman SB; Horowitz JD
    J Am Coll Cardiol; 2004 Jul; 44(1):57-62. PubMed ID: 15234407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relevance of T-type calcium antagonists: a profile of mibefradil.
    Glasser SP
    J Clin Pharmacol; 1998 Aug; 38(8):659-69. PubMed ID: 9725540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two structurally different T-type Ca 2+ channel inhibitors, mibefradil and pimozide, protect CA1 neurons from delayed death after global ischemia in rats.
    Bancila M; Copin JC; Daali Y; Schatlo B; Gasche Y; Bijlenga P
    Fundam Clin Pharmacol; 2011 Aug; 25(4):469-78. PubMed ID: 21039820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of mibefradil on heart rate variability in patients with chronic heart failure.
    Tjeerdsma G; Brouwer J; de Kam PJ; Haaksma J; Crijns HJ; van Veldhuisen DJ
    Int J Cardiol; 2000 Mar; 73(1):55-60. PubMed ID: 10748311
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Physiologic and pathophysiologic relevance of T-type calcium-ion channels: potential indications for T-type calcium antagonists.
    Hermsmeyer K; Mishra S; Miyagawa K; Minshall R
    Clin Ther; 1997; 19 Suppl A():18-26. PubMed ID: 9385502
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cardioprotective efficacy of verapamil and mibefradil in young UM-X7.1 cardiomyopathic hamsters.
    Paquette F; Jasmin G; Dumont L
    Cardiovasc Drugs Ther; 1999 Nov; 13(6):525-30. PubMed ID: 10686662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of T channels in cardiovascular function.
    Hermsmeyer K
    Cardiology; 1998; 89 Suppl 1():2-9. PubMed ID: 9570423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T-type and L-type calcium channel blockers exert opposite effects on renin secretion and renin gene expression in conscious rats.
    Wagner C; Krämer BK; Hinder M; Kieninger M; Kurtz A
    Br J Pharmacol; 1998 Jun; 124(3):579-85. PubMed ID: 9647484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure.
    Mulder P; Richard V; Compagnon P; Henry JP; Lallemand F; Clozel JP; Koen R; Macé B; Thuillez C
    J Am Coll Cardiol; 1997 Feb; 29(2):416-21. PubMed ID: 9014998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rationale for the use of calcium antagonists in the treatment of silent myocardial ischemia.
    Cohn PF
    Clin Ther; 1997; 19 Suppl A():74-91. PubMed ID: 9385506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative effects of mibefradil and nifedipine gastrointestinal transport system on autonomic function in patients with mild to moderate essential hypertension.
    Pellizzer AM; Kamen PW; Esler MD; Lim S; Krum H
    J Hypertens; 2001 Feb; 19(2):279-85. PubMed ID: 11212971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Blocking of T-type calcium channels: new horizons in the therapeutic potential of calcium antagonists].
    Cerqueira-Gomes M; Maciel MJ; Martins L
    Rev Port Cardiol; 1998 Jan; 17(1):9-15. PubMed ID: 9558949
    [No Abstract]   [Full Text] [Related]  

  • 40. [Calcium channel blockers in the treatment of ischemic heart disease].
    Bultas J
    Vnitr Lek; 1995 Mar; 41(3):167-8. PubMed ID: 7762171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.